The report suggests with moderate certainty that all 3 therapies offer a small or substantial net health benefit and with a high certainty of at least a small net health benefit.
Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.
Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.
New classes of acute migraine therapies on the cusp of FDA approval look to fill in long-standing gaps in care.
Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.
Epidemiology studies are useful to clinicians because they highlight diagnosis and prescribing patterns, common trends within a disease, and unmet needs.
At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.
Food insecurity and migraine, anxiety sensitivity and migraine severity, supraorbital stimulation to prevent chronic migraine—find summaries of these and other recent findings here.
Physicians should ask patients about their history of headaches and monitor for possible indicators of stroke, especially among older individuals who are already at increased risk.
Discussed in this video: Several novel modalities centered around migraine treatment and prevention.